We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





10-Minute COVID-19 Diagnostic Test Based on Nanoparticles Identifies IgG Antibodies and Costs Only Fifth of Market Average

By LabMedica International staff writers
Posted on 04 Feb 2021
A new COVID-19 test uses technology based on nanoparticles to detect antibodies to the novel coronavirus in 10 minutes and costs only a fifth of the market average.

The test developed by researchers at the University of São Paulo’s São Carlos Chemistry Institute (IQSC-USP; São Paulo, Brazil) and Biolinker (São Paulo, Brazil) works similarly to the rapid tests available now in pharmacies. More...
It analyzes a drop of blood, and two red LEDs light up if it detects the presence of immunoglobulin G (IgG) antibodies, which are produced in the acute phase of COVID-19 (10 days after the onset of symptoms on average). According to the researchers, the technology can easily be adapted to the novel SARS-CoV-2 variants, if necessary.

The test can be sold for less than USD 6 after it receives regulatory approval thanks to efforts by the researchers to optimize the quantity of raw materials and reagents in order to lower its production cost and develop a technology based on nanoparticles to facilitate IgG detection. The researchers combined a gold nanoparticle (which originates the red color) with a piece of the virus’s spike protein recognized by human antibodies. To develop the molecule used in the test device, the researchers worked in the laboratory to synthesize the docking tip of the spike protein, known as the receptor-binding domain (RBD), and used a recombinant DNA technology involving bacteria genetically modified to express the viral protein in vitro.

“The more antibodies there are in the blood, the brighter the red color. We believe this means the test can also be used to monitor the response to vaccination,” said Frank Crespilho, a professor at IQSC-USP and principal investigator for the study.

Related Links:
University of São Paulo
Biolinker



Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Online QC Software
Acusera 24•7
Chromogenic Culture System
InTray™ COLOREX™ ECC
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.